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Under conditions of hypoxia, most eukaryotic cells undergo
a shift in metabolic strategy, which involves increased flux
through the glycolytic pathway. Although this is critical for
bioenergetic homeostasis, the underlying mechanisms have
remained incompletely understood. Here, we report that the
induction of hypoxia-induced glycolysis is retained in cells
when gene transcription or protein synthesis are inhibited sug-
gesting the involvement of additional post-translational mech-
anisms. Post-translational protein modification by the small
ubiquitin related modifier-1 (SUMO-1) is induced in hypoxia
and mass spectrometric analysis using yeast cells expressing
tap-tagged Smt3 (the yeast homolog of mammalian SUMO)
revealed hypoxia-dependent modification of a number of key
glycolytic enzymes. Overexpression of SUMO-1 in mammalian
cancer cells resulted in increased hypoxia-induced glycolysis
and resistance to hypoxia-dependent ATP depletion. Support-
ing this, non-transformed cells also demonstrated increased
glucose uptake upon SUMO-1 overexpression. Conversely,
cells overexpressing the de-SUMOylating enzyme SENP-2
failed to demonstrate hypoxia-induced glycolysis. SUMO-1
overexpressing cells demonstrated focal clustering of glyco-
lytic enzymes in response to hypoxia leading us to hypothesize
a role for SUMOylation in promoting spatial re-organization
of the glycolytic pathway. In summary, we hypothesize that
SUMOmodification of key metabolic enzymes plays an impor-
tant role in shifting cellular metabolic strategies toward in-
creased flux through the glycolytic pathway during periods of
hypoxic stress.
In the steady state (when oxygen levels within a cell exceed
bioenergetic requirements), activity of the glycolytic pathway,
the TCA (tricarboxyic acid) cycle and electron transport
chain combine to generate38 molecules of adenosine
triphosphate (ATP) per molecule of glucose metabolized. Gly-
colysis and the TCA cycle each generate 2 molecules of ATP
with the remaining 34 molecules being produced during oxi-
dative phosphorylation. This process provides the ATP neces-
sary to maintain physiologic function. However, under condi-
tions where oxygen demand exceeds supply (hypoxia), most
cells retain the capacity to fundamentally shift metabolic
strategy to a state where mitochondrial activity is decreased
and glycolysis becomes the primary pathway for ATP genera-
tion (1). Normally, this metabolic switch promotes cell sur-
vival during hypoxia and is thus adaptive in nature. In such
cases, cells switch back to the predominantly oxidative metab-
olism when the oxygen balance is restored. This phenomenon
is known as the Pasteur effect (3). Alternatively, in the hy-
poxic compartment of a growing tumor, which has outgrown
the local blood supply, the ability of cells to develop enhanced
glycolytic metabolism confers a survival advantage for the
tumor. Furthermore, some cancer cells develop the ability to
maintain enhanced glycolysis even when sufficient oxygen
supply returns, a phenomenon known as the Warburg effect
(35). Thus, the ability of cells to increase the rate of glycolysis
in response to hypoxia has important implications in both
health and disease. The molecular mechanisms underlying
these important switches in metabolic function are an area of
intense investigation.
One mechanism that underpins hypoxia-induced increase
in flux through the glycolytic pathway involves transcriptional
up-regulation of glycolytic enzymes by the hypoxia-inducible
transcription factor, HIF (3). In the current study, we provide
data that, in addition to this transcriptional pathway, a non-
transcriptional mechanism involving post-translational modi-
fication of key glycolytic enzymes facilitates the rapid increase
in glycolysis that occurs during hypoxia.
The small ubiquitin related modifier (SUMO)2 protein fam-
ily is a family of three small proteins of17 kDa in mammals
and one member in the yeast Saccharomyces cerevisiae, which
modify a wide range of target molecules (10, 11, 27). In S. cer-
evisiae, the SUMO homologue Smt3 has been shown to be
essential for viability (10, 11). Recent work has demonstrated
that HIF-1 itself is a target for SUMOmodification (12, 15,
16, 18–20). The first identified targets for SUMOmodifica-
tion were mostly nuclear transcription factors. However,
more recent work has identified a number of cytoplasmic
SUMO targets (13). Extranuclear roles for protein SUMO-1
modification include regulation of G protein signaling, regula-
tion of kinase/phosphatase activity, axonal mRNA trafficking,
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mitochondrial fission/fusion, glucose transport, and gluta-
mate receptor function as well as regulation of neuronal in-
tegrity and synaptic function (21, 27, 37). More recently, a
growing number of studies have linked the SUMOmodifica-
tion pathway with tumor development and metastasis and as
a response to DNA damage (28, 38).
We and others have shown that upon exposure of cells to
hypoxia, there is an altered pattern of protein modification by
SUMO-1 (2, 14–16). Furthermore, a number of studies have
demonstrated enhanced protein SUMOmodification in hi-
bernation and transient ischemic episodes, both of which
involve significant decreases in tissue perfusion and oxygen-
ation (22–26). However, to date, the physiological implica-
tions for SUMOmodification in hypoxia have remained
largely unknown.
In the current study we found that even when gene tran-
scription and translation were inhibited, hypoxia-induced flux
through the glycolytic pathway, leading us to hypothesize a
role for post-translational modifications in hypoxia-induced
glycolysis. Because SUMO-1 modification has previously been
shown to be increased in hypoxia in a range of models, we
used a proteomic approach in S. cerevisiae to identify the pro-
teins modified by Smt3 (the yeast homolog of mammalian
SUMO) in hypoxia with an aim to identifying a possible gen-
eral physiologic role for this modification. We found that a
number of key metabolic enzymes were modified by Smt3 in
hypoxic yeast. In mammalian cells, overexpression of
SUMO-1 enhanced basal and hypoxia-induced glycolysis and
glucose uptake. Conversely, overexpression of the SUMO
isopeptidase SENP2 reversed hypoxia-induced glycolysis. We
hypothesize that SUMOmodification of metabolic enzymes is
involved in the promotion of glycolysis in mammalian cells
thus favoring a shift to glycolytic ATP generation. This com-
pliments transcriptional up-regulation of glycolytic enzymes
by HIF-dependent pathways and promotes metabolic adapta-
tion to hypoxia, an event that may contribute to tumor cell
survival.
MATERIALS ANDMETHODS
Reagents—Mouse anti-GMP-1 (SUMO-1) antibody was
purchased from Zymed Laboratories Inc. (San Francisco, CA),
mouse anti-GAPDH from Calbiochem (Darmstadt, Ger-
many), rabbit anti-GAPDH, goat biotin, anti-pyruvate kinase,
and rabbit anti-HIF-1 antibodies were purchased from Ab-
cam (Cambridge, United Kingdom), mouse anti-His6 was ob-
tained from Roche Applied Science (Basel, Switzerland). All
secondary antibodies used for immunoblotting were obtained
from Cell Signaling (Danvers, MA), whereas those used for
immunofluoresence were obtained from the Jackson Labora-
tory (Westgrove, PA). The SENP2 adenovirus and His6
SUMO-1 overexpressing HeLa cells were kind gifts from Pro-
fessor Ron Hay of the University of Dundee.
Cell Culture—Human cervical adenocarcinoma cells
(HeLa) were cultured in minimum essential medium contain-
ing glutamine supplemented with 10% FCS, 100 units/ml of
penicillin/streptomycin. Cells were placed in one of two hy-
poxia chambers (Coy Laboratories, Grass Lake, MI) or a tissue
culture incubator allowing the establishment of graded, hu-
midified ambient atmospheric hypoxia of 21, 10, and 1% O2
with 5% CO2 and a balance of N2 in all cases. Extracellular
medium pO2 measurements were monitored using fluores-
cence quenching oxymetry (Oxylite-2000; Oxford Optronix,
Oxford, UK). This degree of hypoxic exposure used in these
experiments did not induce cell death via apoptosis or necro-
sis (data not shown). Temperature was maintained at 37 °C in
a humidified environment.
ATP Measurements—To measure cellular ATP levels, a
commercial assay kit was used according to the manufactur-
er’s instructions (Promega). Briefly, cells were maintained in
60-mm dishes in normoxia or hypoxia for the indicated peri-
ods. Whole cells lysates were generated using the luciferase
reporter lysis buffer. Samples were protein normalized and
the intracellular ATP levels were determined using a lucife-
rin-luciferase assay with luminescence being measured on a
desktop luminometer (Berthold Technologies Junior LB
9509). Measurements are expressed as micromolar ATP (rela-
tive light units).
Lactate Assay—Lactate levels in the medium were mea-
sured using a commercially available kit (Trinity Biotechnol-
ogy). Briefly, 2.0 105 cells were maintained either in nor-
moxia or hypoxia on 60-mm tissue culture plates for 24 h in
phenol red-free medium. Lactate levels from the cells were
measured on a 96-well plate using a lactate assay kit.
Immunoblotting—Protein samples were resolved on a 10%
SDS-polyacrylamide gel by electrophoresis and transferred to
nitrocellulose membranes (Bio-Rad). Protein patterns on the
membranes were visualized by staining with Ponceau S prior
to blocking with 5% nonfat skim milk in TBST for 1 h fol-
lowed by overnight incubation with the primary antibody at
4 °C (mouse anti-His6 or HIF-1 (1:500)). Membranes were
washed (with TBST) for 1 h and incubated with the appropri-
ate horseradish peroxidase-labeled secondary antibodies at
room temperature for a further hour (Santa Cruz). Specific
bands were identified using enhanced chemiluminescence
and development on an x-ray film. Band density was quanti-
fied by densitometry.
Tandem Affinity Purification—Cells were grown in nor-
moxia or hypoxia for the indicated periods, scraped in ice-
cold PBS, and centrifuged to generate a cell pellet. The cell
pellet was washed twice in ice-cold PBS. The cells were lysed
in 5 ml of lysis buffer (10% glycerol, 50 mM HEPES-KOH, pH
8.0, 100 mM KCl, 2 mM EDTA, 0.05% Nonidet P-40, and 0.25
mM sodium orthovanadate) for 30 min on ice, after which,
two freeze-thaw cycles were used to improve protein recov-
ery. The lysate was spun at 28,000 g for 1 h to remove any
cell debris.
25 ml of IgG-Sepharose 6 fast flow beads were washed
three times in lysis buffer before being added to the cleared
lysate. The lysate was incubated on a rotor at 4 °C for 4 h. The
lysate was then poured gently into a 1-ml column. The recov-
ered beads were then washed three times with 1 ml of lysis
buffer and three times with 1 ml of TEV buffer (10 mM
HEPES-KOH, pH 8.0, 150 mM NaCl, 0.1% Nonidet P-40, 0.5
mM EDTA, and 1 mM DTT). The beads were resuspended in 1
ml of TEV buffer and 100 units of TEV enzyme added. The
slurry was incubated with gentle agitation overnight at 4 °C.
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The column was drained but the supernatant was retained
in a 15-ml tube. The beads were washed three times with cal-
modulin binding buffer (10 mM -mercaptoethanol, 10 mM
HEPES-KOH, pH 8.0, 150 mM NaCl, 1 mM MgOAc, 1 mM
imidazole, 0.1% Nonidet P-40, and 2 mM CaCl2), each time
the wash supernatant was transfer to the 15-ml tube. 16 ml of
a 1 M CaCl2 solution was added to the protein mixture before
25 ml of washed calmodulin-Sepharose 4B beads were added.
This solution was transferred to a new column and incubated
at 4 °C for 90 min.
Again the column was drained and the beads were washed
five times in calmodulin wash buffer (10 mM -mercaptoetha-
nol, 10 mM HEPES-KOH, pH 8.0, 150 mM NaCl, 1 mM
MgOAc, 1 mM imidazole, 0.05% Nonidet P-40, and 2 mM
CaCl2). The beads were resuspended twice for 5 min and once
for 15 min, in 340 ml of calmodulin elution buffer (10 mM
-mercaptoethanol, 10 mM HEPES-KOH, pH 8.0, 150 mM
NaCl, 1 mM MgOAc, 1 mM imidazole, 0.05% Nonidet P-40,
and 25 mM EGTA) to elute the resulting protein complex.
Eluted protein complexes were precipitated with trichloro-
acetic acid and resuspended in 2 sample buffer (125 mM
Tris-HCl, pH 6.8, 4% (w/v) SDS, 0.1% (w/v) bromphenol blue,
20% (w/v) glycerol) by boiling at 100 °C for 5 min. Samples
were resolved on a 4–20% pre-cast gel and stained with Coo-
massie stain. The lanes containing the resolved proteins were
cut into gel slices from the top to the bottom of the gel. The
gel slices were then subjected to trypsin digestion.
For LC-MS/MS analysis, protein digests were injected us-
ing an autosampler onto an LC Packing PepSep column (75
mm inner diameter, 150 mm). Nano-HPLC was used to sepa-
rate peptides. Two solvents, A and B (A: 0.1% formic acid; B:
0.1% formic acid in 100% MeCN) were used to generate a gra-
dient from 5% B to 55% B over 30 min, then up to 90% B over
5 min and introduced to a LTQ ion trap mass spectrometer
(ThemoFinnegan) using electrospray ionization from a nano-
flow probe at 300 nl/min. Full MS scans were recorded on the
eluting peptides over the 600–2000m/z range. TandemMS
(MS/MS) spectra were acquired at 35% collision energy in a
data-dependent manner, sequentially on the first to 10th most
intense ion selected from the full MS scan. MS/MS data were
analyzed using X-tandem and searched against a Uniprot data
base. All positive proteins identified were only accepted if
they had a X-tandem score below5.
GAPDH Activity Assay—To measure GAPDH enzymatic
activity, the KDalertTM GAPDH Assay kit (Ambion Inc.) was
used according to the manufacturer’s instructions. Briefly,
cells exposed to hypoxia for different periods of time were
washed with ice-cold PBS and then 1 ml of lysis buffer (sup-
plied with the kit) was added and agitated at 4 °C for 20 min.
Cells were then scraped and transferred into labeled micro-
centrifuge tubes. 20 l of the lysates were mixed with 180 l
of the master mixture, left for 15 min at room temperature,
and the absorbance measured at 615 nm. Each experiment
was preceded by a GAPDH standard curve using recombinant
GAPDH enzyme from where the concentrations of GAPDH
for the samples were obtained and expressed in units/ml.
Glucose Uptake Assay—Mouse embryonic fibroblasts
(MEF) were grown in Dulbecco’s modified Eagle’s medium
supplemented with 10% fetal calf serum (FCS). Cells were
transfected using lipofection (FuGENE, Roche Applied Sci-
ence) with 0.5 g of either plasmid DNA encoding the His6-
SUMO-1 protein (Ron Hay, University of Dundee, UK) or
pcDNA3 empty vector. A colorimetric glucose assay (Biovi-
sion) was used to determine the effect of hypoxia on glucose
uptake. Briefly, conditioned medium from the cell cultures
were collected and the glucose level was measured according
to the manufacturer’s protocol.
Infection of Cells with SENP2 Adenovirus—Cells were in-
fected with SENP2 adenovirus, exposed to hypoxia, and their
metabolic activity analyzed. Briefly, 25,000 HeLa cells per well
were seeded in 24-well plates and maintained for 24 h. 900 l
of the medium was removed from the cells leaving 100 l on
the cells onto which 2 l of SENP2 adenovirus or 1 l of GFP
adenovirus control were added and left for 2 h before adding
900 l of medium. Infected cells were left in the incubator for
48 h, medium was replaced with phenol red-free medium be-
fore being exposed to 1% O2 or left in normoxia for a further
24 h.
Immunofluorescence—1 104 cells were seeded on 10-mm
coverslips in four-well plates and grown overnight. Cells were
maintained in normoxia or hypoxia (1% O2) for 18–24 h be-
fore immunofluorescence studies were carried out. Unless
otherwise indicted all washes were 5 min. Briefly, cells were
washed twice with ice-cold PBS before fixation with 5%
paraformaldehyde/PBS for 15 min. Following two washes in
PBS, cells were washed with 50 mM ammonium chloride in
PBS for 15 min to quench the free aldehyde groups. Cover-
slips were washed with PBS twice before being transferred to
a humidified chamber where 50 l of the appropriate dilu-
tions of the primary antibodies diluted in 5% FCS/PBS (anti-
mouse GAPDH, 1:200) were added and incubated for 1 h at
room temperature. This is followed by two PBS washes and
then incubated with 50 l of a 1:200 dilution (diluted in 5%
FCS/PBS) of the appropriate species-labeled secondary anti-
bodies (FITC for anti-mouse or Texas Red for anti-goat) for
45 min at room temperature covered with aluminium foil.
After 45 min, the coverslips were washed twice with PBS,
rinsed in distilled water, and mounted on ethanol-cleaned
glass slide fluorescent mounting medium and left overnight.
Slides were examined and images were acquired on an upright
fluorescent microscope (Zeiss) using the Axiovision image
analysis program.
Statistical Analysis—All data are presented as mean S.E.
for n independent experiments. Statistical significance was
evaluated by one-tailed paired Student’s t test (asterisk corre-
sponds to p 0.05 (n 3–6 for each individual experiment)).
RESULTS
Hypoxia Increases Glycolysis in Mammalian Cells—Hy-
poxia induces a shift in cellular metabolism from oxidative
phosphorylation to glycolysis in most eukaryotic cell types (1,
3, 9). To confirm this response in a transformed tumor cell
line, HeLa cells were exposed to graded decreases in atmo-
spheric oxygen (from 21 to 1% O2) for 24 h and ATP levels
were determined. Graded decreases in oxygen resulted in an
initial decrease in ATP between 21 and 5% atmospheric oxy-
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gen, which then leveled off indicating that anaerobic ATP
production predominates at lower oxygen concentrations
(Fig. 1A). The maintenance of ATP levels at low O2 was ac-
companied by an increase in lactate production reflecting an
increased glycolysis in hypoxia (Fig. 1B). Enhanced lactate
production in HeLa cells exposed to hypoxia is also demon-
strated in time course studies (supplemental Fig. S1). Thus,
although highly transformed and glycolytic, HeLa cells ex-
posed to severe hypoxia undergo a shift in metabolism to a
higher degree of flux through the glycolytic pathway.
Increased glycolysis during hypoxia has been attributed to
the induction of transcription factor HIF with subsequent
expression of glycolytic genes (3). Consistent with this, we
found that hypoxia rapidly and reversibly induces HIF-1
expression within 5 min (Fig. 1C). This is reflected by in-
creased expression of glycolytic enzymes including phospho-
glycerate kinase and GAPDH (supplementary Fig. S2). How-
ever, in HeLa cells treated with either actinomycin D (an
inhibitor of gene transcription) or cycloheximide (an inhibitor
of protein synthesis) in concentrations that inhibit increased
glycolytic enzyme expression, increased lactate production
was still detectable in hypoxia (Fig. 1, D and E, and supple-
mental Fig. S1). Thus, a degree of hypoxia-induced glycolysis
occurs even when new gene or protein synthesis is blocked.
These data lead us to the hypothesis that post-translational
mechanisms may play a role in the switch to increased glycol-
ysis in hypoxia.
One such post-translational modification that we have pre-
viously shown to be enhanced in hypoxic and ischemic condi-
tions is by SUMO-1 (2), leading us to the hypothesis that
post-translational protein modification by members of the
SUMO family may contribute to the regulation of cellular
metabolism during hypoxia.
Hypoxia Increases Protein Sumoylation—We next con-
firmed previous reports (2, 14–16) that hypoxia increases glo-
bal protein modification by SUMO-1, utilizing HeLa cells
overexpressing His6-SUMO-1. Cells exposed to a time course
of hypoxia (1% atmospheric oxygen) demonstrated decreased
FIGURE 1. Hypoxia increases cellular glycolysis and decreases ATP generation. A, HeLa cells were exposed to graded hypoxia (21, 10, and 1% for 24 h)
and ATP levels were determined. B, HeLa cells were exposed to graded hypoxia and the rate of glycolysis was determined by measuring lactate generation.
C, HeLa cells were exposed to 1% oxygen for the indicated time points and whole cell lysates were immunoblotted for HIF-1. HIF-1 levels were quantified
by densitometry (lower panel). D, cells were treated with 0–50 ng/ml of actinomycin D prior to exposure to hypoxia and lactate production was measured.
E, cells were exposed to 5–10g/ml of cycloheximide (CHX) before being exposed to hypoxia for 24 h and lactate levels were determined (n 3; *, p 0.05).
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cellular oxygen levels as determined by oxygen-quenching
fluorimetry (Fig. 2A). Consistent with previous studies, this
was matched by global patterns of increased protein
SUMOylation (Fig. 2B). We next used an unbiased proteomic
approach to identify possible targets of modification with the
aim of identifying a possible physiologic role. To do this we
used S. cerevisiae expressing tap-tagged Smt3. Although
mammalian cells express three isoforms of SUMO, Smt3 is
the only homologue in S. cerevisiae (10, 11). Consistent with
mammalian cells, yeast cells expressing tap-tagged Smt3 ex-
posed to graded hypoxia (10, 3, and 1% O2 levels) for 48 h
demonstrated a global increase in protein modification by
Smt3 in response to hypoxia. The bands were excised from
the gels, trypsin digested, and those proteins modified by
Smt3 in hypoxia were identified by mass spectrometry. This
analysis identified a set of proteins involved in cellular metab-
olism of which a subset were glycolytic enzymes, suggesting
that increased protein modification by Smt3 in yeast may play
a role in regulating cellular glycolysis in hypoxia (Fig. 2C,
right).
SUMO-1 Overexpression Enhances Glycolysis in Normoxia
and Hypoxia—The data presented thus far led us to hypothe-
size a role for Smt3 modification in hypoxia-induced glycoly-
sis in yeast. To test whether SUMOylation plays a role in hy-
poxia-induced glycolysis in mammalian cells, we measured
the activity of the glycolytic enzyme GAPDH in SUMO-1
overexpressing HeLa cells exposed to hypoxia relative to wild-
type cells. Exposure to hypoxia increased GAPDH activity in
wild-type cells (Fig. 3A). Furthermore, GAPDH activity in
SUMO-1 overexpressing cells was significantly higher than
that in wild-type cells exposed to hypoxia. Also, the basal ac-
tivity of GAPDH in SUMO-1 overexpressing cells was higher
than in HeLa cells. We further demonstrated that SUMO-1
overexpressing cells generate significantly higher amounts of
lactate in hypoxia compared with control cells (Fig. 3B) sug-
gesting that SUMO-1 modification increases overall glycolytic
flux in hypoxia. These results demonstrate that SUMO-1
overexpression increases hypoxia-induced GAPDH activity
and lactate production.
To test whether the increased hypoxia-induced glycolysis
observed in SUMO-1 overexpressing cells is a function of pro-
tein sumoylation, HeLa cells growing on 24-well plates were
infected with SENP2 adenovirus (which results in global de-
sumoylation) or GFP control adenovirus for 48 h before expo-
sure to 1% O2 for 24 h and the lactate levels in the culture me-
dium were measured. SENP2 is a SUMO isopeptidase enzyme
FIGURE 2. Hypoxia increases global protein sumoylation. A, HeLa cells overexpressing His6-tagged SUMO-1 were exposed to normoxia or hypoxia (1%
O2; 0–48 h). Extracellular pO2 values were measured by fluorescence quenching oxymetry. B, Western blot analysis for SUMO-1-modified proteins in whole
cell extracts from His6-tagged SUMO-1 overexpressing HeLa cells using an anti-His antibody reveals a time-dependent increase in sumoylation patterns in
hypoxia. C, yeast cells overexpressing tap-tagged Smt3 were exposed to graded hypoxia (21 to 1% O2) for 48 h. Samples were separated by gel electro-
phoresis following tap-tag pulldown, the silver stain demonstrates increased Smt3 protein modification. Smt3-modified proteins that were identified by
mass spectrometry included multiple metabolic enzymes.
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that efficiently removes SUMO-1 from all modified proteins.
As shown in Fig. 3C, SENP2 overexpression resulted in a sig-
nificant decrease in lactate levels in hypoxia compared with
uninfected cells or GFP adenovirus-infected cells. These data
demonstrate that general protein desumoylation reverses the
increased lactate production normally observed in hypoxia
lending further evidence to the hypothesis that protein
sumoylation is in part required for the increased glycolytic
flux that occurs in hypoxia.
As the principal objective of increased glycolysis in hypoxia
is increased anaerobic generation of ATP to support cell sur-
vival, we next examined whether the increased glycolytic ca-
pacity of the SUMO-1 overexpressing cells is coupled to ATP
generation. Wild-type and SUMO-1 overexpressing HeLa
cells were exposed to 1% oxygen for 24 h following which the
ATP levels in the cells were measured. As shown in Fig. 3D,
wild-type cells exposed to hypoxia demonstrated a significant
decrease in ATP levels compared with normoxic cells. Basal
ATP levels were lower in SUMO-1 overexpressing cells, how-
ever, the resulting hypoxia did not cause a decrease in cellular
ATP consistent with the hypothesis that the increased glycol-
ysis in these cells is accompanied by glycolytic ATP produc-
tion and is independent of oxygen.
To test whether SUMO overexpression increases glucose
metabolism in a non-transformed cell type, we used MEF.
Overexpression of SUMO in MEF resulted in a dramatic in-
crease in glucose uptake in normoxia (Fig. 3E) supporting a
role for sumoylation in the promotion of glucose metabolism.
Hypoxia also greatly enhanced glucose uptake but this was
not effected by SUMO overexpression, indicating that glucose
transporters may be operating at maximum activity in hy-
poxia and that overexpression of SUMO cannot further in-
crease this activity.
Hypoxia Alters Spatial Organization of Glycolytic Enzymes—
We next sought to gain mechanistic insights into how
SUMOylation may be impacting upon the glycolytic pathway.
FIGURE 3. SUMO-1 overexpressing cells demonstrate an enhanced cellular glycolytic capacity. A, measurement of GAPDH enzymatic activity in cells
demonstrates that overexpression of SUMO-1 leads to increased GAPDH activity both in normoxia and hypoxia. B, cells overexpressing SUMO-1 (white bars)
demonstrate increased lactate production in both normoxia and hypoxia when compared with control cells (black bars) reflecting increased glycolytic activ-
ity. C, infection of HeLa cells with adenovirus overexpressing SENP2 results in a reversal of hypoxia-induced increase in lactate generation. D, total cell ATP
levels decrease with hypoxia in wild-type cells but not in SUMO-1 overexpressing cells consistent with a role for SUMO-1 in the positive regulation of glyco-
lytic metabolism. E, glucose uptake in MEF cells transfected with His-SUMO-1 or pCDNA plasmid control. MEF cells transfected with 0.5 g of SUMO-1 plas-
mid show increased glucose uptake in normoxia compared with control cells. Data are presented as mean S.E. for at least n 3–6 independent experi-
ments; *, p 0.05, unpaired Student’s t test.
SUMOandGlycolysis in Hypoxia
FEBRUARY 11, 2011•VOLUME 286•NUMBER 6 JOURNAL OF BIOLOGICAL CHEMISTRY 4723
 at A
STO
N
 U
N
IV
ERSITY
 on A
ugust 20, 2018
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
Post-translational modification of proteins by SUMO-1 has
been reported to modulate protein-protein interactions, nu-
cleocytoplasmic transport, as well as subcellular localization
and stability of the modified proteins (8, 25).
Based on these known effects of SUMOmodification of
target proteins, we investigated the effect of sumoylation on
expression, localization, and spatial organization of GAPDH,
a key glycolytic enzyme. HeLa cells and His6-SUMO-1 over-
expressing cells were maintained in normoxia (21% O2) or
exposed to 1% O2 for 24 h and immunostained with antibod-
ies for GAPDH. As shown in Fig. 4A, GAPDH is expressed in
both the cytosol and nucleus. Hypoxia increases both the ex-
pression and focal speckling of GAPDH in HeLa cells exposed
to hypoxia. This effect is significantly enhanced in SUMO-1
overexpressing cells as the punctuate staining and the speck-
les become more prominent (Fig. 4A). Co-immunostaining
for GAPDH and pyruvate kinase (another glycolytic enzyme)
demonstrates that in SUMO-1 overexpressing cells hypoxia
results in co-localization of the two enzymes (Fig. 4A, lower
panel) suggesting that protein sumoylation may promote the
interaction or spatial organization of glycolytic enzymes.
These results lead us to hypothesize that SUMO-1 modifica-
tion of glycolytic enzymes promotes their co-localization and
facilitates substrate channeling and flux through the glycolytic
pathway during hypoxia.
DISCUSSION
Under steady state conditions, the primary method of ATP
generation for most eukaryotic cells is aerobic respiration in-
volving the combined activities of the glycolytic pathway, the
TCA cycle, and the electron transport chain (1, 9). Collec-
tively, these processes allow the efficient generation of38
molecules of ATP per molecule of glucose completely metab-
olized. When oxygen is limited, cells must change their meta-
bolic strategy to sustain ATP generation. Because glycolysis
alone generates a small net amount of ATP (2 molecules per
molecule of glucose metabolized) without the requirement of
oxygen, one metabolic option for cells is to enhance the rate
of glycolysis such that this pathway becomes the primary
source of cellular ATP generation, whereas actively decreas-
ing oxidative phosphorylation. For this to occur, a significant
elevation in the rate of glycolytic activity is required. One
method by which this may be facilitated is through transcrip-
tional up-regulation of glycolytic enzymes and glucose trans-
porters, an event governed by the master regulator of hypoxi-
a-dependent gene expression, HIF-1 (3). Supporting this,
HIF-1-dependent alterations in critical regulators of mito-
chondrial respiration favor a decrease in activity of the TCA
cycle and the mitochondrial electron transport chain, respec-
tively, leading to decreased oxidative stress (4–9). We hy-
pothesized that these transcriptional events are supported by
posttranslational modification of metabolic enzymes that fa-
cilitate a rapid shift in the metabolic strategy of a cell when
challenged with an acute hypoxic insult.
Modification of proteins by the small ubiquitin-related
modifier SUMO is critical in a range of cellular physiological
processes. We and others have previously demonstrated that
hypoxia alters the profile of SUMO-modified proteins (2, 14–
16). In the current study, we have demonstrated that hypoxia
increases SUMO-1 modification of metabolic enzymes, which
is accompanied by enhancement of the glycolytic pathway
leading us to the hypothesis that such a modification may
positively regulate glycolysis and promote the generation of
ATP in the absence of oxygen. Three key questions remain in
the development of our understanding of the implications of
this finding.
First, what is the hypoxia-sensing mechanism underlying
SUMO-1 modification of metabolic proteins? Although the
functional importance of protein sumoylation has been de-
scribed, the regulation of sumoylation is currently poorly un-
derstood. A recent publication has provided evidence for an
inverse relationship between oxidative stress and activation of
the cellular sumoylation machinery (17). In these studies, it is
proposed that decreased oxidative stress is related to en-
hanced protein sumoylation. This effect is thought to be due
to reactive oxygen species sensitivity of desumoylating en-
zymes. Because the production of reactive oxygen species is
related to aerobic respiration in cells through the proton leak,
it is possible that decreased reactive oxygen species produc-
tion in hypoxia as a result of decreased activity of the electron
FIGURE 4.Hypoxia alters spatial organization of GAPDH into speckles in
SUMO-1 overexpressing cells. A, HeLa cells (control) and SUMO-1 overex-
pressing cells were maintained in normoxia or exposed to hypoxia and
GAPDH was localized by immunofluorescence (green). B, immunofluores-
cence co-staining of GAPDH (green) and pyruvate kinase (red) in wild-type
and SUMO-1 overexpressing HeLa cells exposed to hypoxia.
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transport chain leads to a subcellular microenvironment fa-
vorable to increased sumoylation of glycolytic enzymes.
Second, a critical question relates to the source of SUMO-1
for protein modification in hypoxia. In the steady state, the
majority of SUMO-1 is conjugated to proteins with little free
SUMO-1 available (27). This leads to two possibilities: first,
that de novo production of SUMO-1 in hypoxia provides the
pool with which to modify the metabolic enzymes. We and
others have previously demonstrated that hypoxia up-regu-
lates expression of SUMO-1 mRNA and protein expression
(2, 14–16). An alternative explanation for our observation of
increased SUMO-1 modification in hypoxia may be a redistri-
bution of SUMO-1 in hypoxia from substrates preferentially
modified in normoxia to those preferentially modified in hy-
poxia. In support of this, several studies have recently re-
ported changes in the pattern of SUMOmodification in other
cellular stresses including heat shock, electrophil and oxida-
tive stress (17, 30, 31), consistent with the “preferential redis-
tribution” hypothesis.
A third key question relates to how SUMO-1 modification
increases the overall cellular glycolytic activity. One possibil-
ity here is that SUMOmodification of glycolytic enzymes as
well as other metabolic proteins in hypoxia may directly in-
crease enzyme activity. How SUMO-1 modification may func-
tion to increase enzyme activity remains unknown. One
mechanism may be change in enzyme conformation as a re-
sult of the modification that may influence its activity as in
the case with ubiquitination of the deiodinase enzyme where
its modification by ubiquitin results in reversible deactivation
of the enzyme (29). Whether this is the case with GAPDH or
other glycolytic enzymes remains unknown.
Alternatively spatial rearrangement of SUMO-1-modified
glycolytic enzymes in the cytoplasm into discreet complexes
with other glycolytic enzymes may allow the generation of
complexes that favor substrate channeling in the glycolytic
pathway thus enhancing overall efficiency of this pathway.
The relative importance of these processes remains to be de-
termined but has been shown to be essential in the glycolytic
pathways of some human protozoan parasites, trypanosomes
(34). Furthermore, a recent study demonstrated the interac-
tion of SUMO-1, the SUMO E3 ligase PIAS3, and the rate-
limiting glycolytic enzyme, pyruvate kinase (36). Whether this
interaction of pyruvate kinase with SUMO has any effects on
its enzyme activity or its interaction with other glycolytic en-
zymes is yet to be investigated.
Finally, the physiological significance of this response re-
mains to be clearly elucidated. We propose that this mecha-
nism may have significance in the rapid adaptation to hy-
poxic/ischemic stress during which cells must switch to a
state of enhanced flux through the glycolytic pathway for
their survival as occurs during physiological processes such as
hibernation and ischemia. Tumor cells on the other hand may
exploit the same strategy to survive as a maladaptive mecha-
nism. The SUMO conjugation pathway has recently been im-
plicated in cancer development and metastasis (28). Several
reports of functional alterations and changes in expression
pattern of components of the SUMO conjugation machinery
in different cancers including prostate cancers and thyroid
adenomas exist (32, 33). A recent study demonstrated a sig-
nificant increase in protein sumoylation in two leukemic cell
lines (HL60 and HL60RV) but more abundant in the vincris-
tine-resistant HL60RV cancer cell line (39). Taken together
such tumors may exploit the SUMO pathway as a metabolic
advantage for their development and survival. In summary,
we have demonstrated that SUMO-1 modification is associ-
ated with enhanced glycolysis indicating a possible role for
this modification in mediating the fundamental shift in meta-
bolic strategy observed when a eukaryotic cell encounters a
hypoxic microenvironment.
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